Key stats
About ProShares Ultra Nasdaq Biotechnology
Home page
Inception date
Apr 7, 2010
Structure
Open-Ended Fund
Replication method
Synthetic
Dividend treatment
Distributes
Distribution tax treatment
Ordinary income
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
ProShare Advisors LLC
Distributor
SEI Investments Distribution Co.
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQ’s biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returns—for good or for ill.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Government
Stocks73.95%
Health Technology68.47%
Commercial Services0.83%
Technology Services0.73%
Health Services0.43%
Process Industries0.02%
Bonds, Cash & Other26.05%
Government30.98%
Miscellaneous0.01%
Cash−4.94%
Stock breakdown by region
North America87.40%
Europe12.31%
Asia0.26%
Oceania0.03%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BIB invests in stocks. The fund's major sectors are Health Technology, with 71.85% stocks, and Commercial Services, with 0.87% of the basket. The assets are mostly located in the North America region.
BIB last dividends amounted to 0.13 USD. The quarter before, the issuer paid 0.40 USD in dividends, which shows a 202.77% decrease.
BIB assets under management is 46.36 M USD. It's fallen 11.23% over the last month.
BIB fund flows account for −30.88 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, BIB pays dividends to its holders with the dividend yield of 2.20%. The last dividend (Apr 1, 2025) amounted to 0.13 USD. The dividends are paid quarterly.
BIB shares are issued by ProShare Advisors LLC under the brand ProShares. The ETF was launched on Apr 7, 2010, and its management style is Passive.
BIB expense ratio is 0.95% meaning you'd have to pay 0.95% of your investment to help manage the fund.
BIB follows the NASDAQ / Biotechnology. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BIB invests in stocks.
BIB price has fallen by −7.64% over the last month, and its yearly performance shows a −20.13% decrease. See more dynamics on BIB price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −9.41% over the last month, showed a −21.53% decrease in three-month performance and has decreased by −18.75% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −9.41% over the last month, showed a −21.53% decrease in three-month performance and has decreased by −18.75% in a year.
BIB trades at a premium (0.02%) meaning the ETF is trading at a higher price than the calculated NAV.